Canada: Canada-Europe Free Trade Agreement: A New Prescription For Drug Patents In Canada

On October 17, Canadian Prime Minister Stephen Harper flew to Brussels to conclude a Comprehensive Economic and Trade Agreement ("CETA"), or free trade deal, with the European Union and its 28 member countries. The EU is a market of 500 million people; CETA, if ratified, could be more significant than NAFTA, the North American Free Trade Agreement between Canada, the United States and Mexico, which came into effect in 1994.

Why CETA Matters to Canadian Insurers and Consumers

The actual draft of CETA has not yet been released, and its implementation will depend upon legislation and regulations which are likely years away from being written. However, governments, prescription drug insurance plan administrators and Canadians who pay for their own prescription drugs will want to pay close attention to CETA's drug patent provisions, which were among the main sticking points in the lengthy negotiations between Canada and the EU.

In Canada, brand-name and generic drugs must meet stringent safety, efficacy and quality standards and cannot be sold without federal government approval in the form of a "notice of compliance" or "NOC". Brand-name drugs are approved on the basis of clinical trials demonstrating safety and efficacy for the proposed uses. Generic drugs are approved on the basis of clinical trials demonstrating bioequivalence to the branded product.

Governments around the world try to balance incentives for the creation of new drugs, usually through the time-limited monopolies provided by patents, against the need to have less expensive generic equivalents brought to market as quickly as possible. In Canada, prior to 1993, the federal government's drug approval process focused exclusively on safety, efficacy and quality, without regard to patent considerations. That all changed in 1993, when the government introduced so-called "linkage" regulations – the Patented Medicines (Notice of Compliance) (or "PMNOC") Regulations – that injected patent considerations into the generic drug approval process. Canada joined a fairly small club of countries that have patent linkage regimes – the U.S. does, but the EU and Japan do not.

Challenges for Pharmaceutical Companies in Canada under PMNOC Regulations

Under the PMNOC Regulations, a brand company lists patents relevant to its products on a public "Patent Register". A generic company that wishes to obtain an NOC for its version of a patented drug must notify the brand company that it has submitted an application for an NOC to Health Canada. The generic company must allege that each patent listed for that drug is invalid, or not infringed, or both, and state the legal and factual basis for these allegations (or agree to wait until all listed patents have expired). Upon receiving this notification from a generic company, the brand company may then bring a court case which automatically defers the issuance of the generic's NOC for up to two years while the litigation plays out. If the brand company wins, a court order will prohibit the government from issuing the generic company's NOC until the relevant patent expires.

The PMNOC Regulations were modelled on the 1984 U.S. Drug Price Competition and Patent Term Restoration Act (the "Hatch-Waxman Act"). However, the PMNOC Regulations did a poor job of implementing Hatch-Waxman in Canada. The resulting system has left most everyone unhappy. In the early days of the PMNOC Regulations, one Federal Court of Appeal judge, referring to the linkage of the patent system (aimed at protecting private property rights) with the drug approval system (aimed at protecting public health), famously remarked that "the union is not a happy one."

Because cases under the PMNOC Regulations are "judicial review" applications, they are decided on a paper record (voluminous expert opinion affidavits, transcripts of out-of-court cross-examinations and legal argument) with no live witnesses, and the door is left open to a subsequent full-fledged patent validity or infringement action on the same patent between the same parties, but potentially with a different result than the PMNOC case. Judges are called upon to decide technically complex, hard-fought cases on the basis of massive paper records and oral argument by lawyers. Generic companies face a bizarre form of double jeopardy: a generic company that obtains its NOC after successfully arguing in a PMNOC case that a patent is invalid, or not infringed, or both, can be (and often is) sued for patent infringement in a full action in which the very same patent may be found valid and infringed. A brand company that loses a PMNOC case (with the result that a generic company receives its NOC) may find that it has no right to appeal – the issuance of an NOC to the generic company means that the PMNOC Regulations have no ongoing role and the brand company's appeal is moot (though the brand company can still bring an infringement action).

CETA Calls for Drug Patent Extensions in Canada

In 2009, when CETA negotiations began, brand-name drug manufacturers, many of which are Europe-based, saw an opportunity to push for reforms. These companies have argued that they need stronger patent protection in order to encourage R&D work in Canada, even while many of them have closed their Canadian R&D operations and pharmaceutical R&D work is increasingly being carried out in countries like Brazil, China and India that are not known for strong intellectual property protection. It appears that the brand companies have been at least partly successful. CETA will not require the EU to implement patent linkage, but it will require Canada to provide a new form of marketing exclusivity (akin to the European "supplementary protection certificate") that will have a duration of up to two years, to compensate brand-name drug companies for delays in Health Canada's review of their new drug applications. The federal government has said that it is "prepared to address" the increased drug costs that provinces may incur as a result of this new form of intellectual property protection.

In addition, it appears that CETA will require Canada to address in some fashion the "mootness" doctrine that prevents brand companies from appealing an unfavourable PMNOC decision if a generic has received its NOC. If the manner in which this reform is implemented eliminates serial litigation on the same patent, this may be a win-win for all concerned, as brands will have full appeal rights in PMNOC cases and generics will no longer face the "double jeopardy" of winning a PMNOC case only to be sued for patent infringement and found liable. On the other hand, if this reform is implemented in a manner that permits the two-year deferral of generic drug approvals under the PMNOC Regulations to be extended, generic companies, insurers, provincial governments and consumers will be negatively affected.

Important questions remain unanswered. Which patented drugs will be eligible for supplementary marketing exclusivity, and for how long? How, if at all, will provincial governments be compensated for increased drug costs, and what about other payers? How exactly will serial litigation on the same patent be eliminated? As always, the devil is in the details, which will be found in the full text of CETA (when it is released) and in the legislation and regulations that will be written to implement it.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.